FDMT - Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD
2024-02-19 20:42:02 ET
Summary
- Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form.
- Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent injections that can maintain vision.
- Several companies are developing long-acting anti-VEGF therapies and gene therapies for wet AMD, offering potential solutions with reduced treatment burden and maintained vision.
- Companies discussed in this article: EYPT, OCUL, FDMT, ADVM, RGNX.
Age-related macular degeneration ((AMD)) is the most common cause of central vision loss and blindness in adults. Wet AMD comprises 25% of all cases of AMD and is characterized by new blood vessel formation in and under the retina. 75% of AMD is due to dry AMD (no new blood vessel formation). However, it can progress to wet AMD in a minority of patients....
Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD